Figure 3. TADC, but not BMDC, require stimulation to respond to alloIgG-IC.
a. Tumor growth following intratumoral injection of PBS, 129S1 IgG or C57Bl/6 IgG (n=6). b. CD86 and MHCII expression on DC incubated with PBS, tumor lysates or alloIgG-IC (n=5). c. TNFα and IL-12 in the supernatants of DC cultured with PBS control, LMP lysate or alloIgG-IC (n=5). d. Proliferation of CD4+ T cells cultured with DC treated with PBS, tumor lysate, or alloIgG-IC (n=5). e. Recurrence of resected LMP and B16 in untreated mice or mice treated with alloIgG-IC-activated BMDC or TADC (n=5). f. p-p38, pERK1/2 and pJNK levels in DC, untreated or incubated with alloIgG-IC. Graphs show arcsinh ratios of phospho-species in DC incubated for 5 min with LMP lysate or alloIgG-IC over baseline levels from unstimulated DC (n=5). g. MHCII and CD86 expression and CFSE internalization by TADC after overnight culture with CFSE-labeled alloIgG-IC (n=4). Experiments were independently repeated at least 3 times and analyzed by Mann–Whitney U test. Asterisk (*) denotes p<0.05 and two asterisks (**) denote p<0.01.